Tagged with medicine

China Dr Jin Li explains Chinese firm HitGen’s unique drug discovery technology platform, how its ability to screen billions of molecules has the potential to significantly increase success rates in early drug discovery, and the next steps for the company’s expansion.   By now, we have a platform of over 500…

Korea Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO), explains the basis for Korea’s success in combating the spread of COVID-19, casts light on the future role of precision medicine, and the current hurdles impeding its widespread adoption.   The pandemic, while tragic, has…

Korea Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian patients, explores the company’s expansion plans into China, Japan, and Southeast Asia, and the synergies in their partnerships with big…

Korea Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big Pharma in their oncology projects, and the potential to become a pan-Asian venture in the future.   It is very…

Korea Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in several global M&A deals in the past year with the end goal of finding a combination of assets that will bring value to both investors and patients. With a US manufacturing facility now…

Hong Kong Alex Wong, CEO of Xcelom sat down with PharmaBoardroom to discuss the company’s non-invasive prenatal testing (NIPT) technology and increasing capacity in the field of screening for chromosomal disorders. Wong sheds light on the Asian diagnostics market and unveils his strategy to expand Xcelom’s offering across Asia.   Our pursuit…

Korea Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to shed light on the company’s origins, its collaboration with Big Pharma, and the ease of gaining capital investment for a…

Taiwan Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their technology’s unique characteristics, how it differs from sequencing technologies in terms of cost and speed, and their strategy for the Asia-Pacific region and beyond.   Our solution is akin to capsule coffee. One machine can…

Korea Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing clinical trials, and the complementarity of oncolytic virus with other gene therapies such as CAR-T.   Oncolytic virus is not…

South Korea South Korea is the 12th largest healthcare market globally with a market size of around USD 20 billion in 2019. With the government’s plans to invest over USD 1.7 billion in its biopharma and biotech sectors over the next five years, the country’s prominence in the global biopharma landscape will…

Generics Arun Narayan of Medicines for Europe’s Value Added Medicines Group has been working to promote the benefits of value added medicines and how real-world evidence must be considered. In a recent interview with PharmaBoardroom he elaborated on what some countries are already doing to adopt Value Added Medicines and the…

Hungary Established in 1997, Medi-Radiopharma is a Hungarian privately held company operating in the field of nuclear medicine, a specialized area of radiology that uses very small amounts of radioactive materials, or radiopharmaceuticals, to examine organ function and structure. Breakthroughs in neurocranial and prostate tumour treatment have brought nuclear medicine into…